of calcein in 2008/MrP1 cells and moderately in 2008wt cells. a subsequent short (24 h) exposure to 2.3 μM l-leucovorin decreased calcein levels again in MrP1-overexpressing cells. Folate deprivation markedly increased growth inhibitory effects of the established MrP1 substrates daunorubicin (~twofold), doxorubicin (~fivefold), and methotrexate (~83-fold) in MrP1-overexpressing cells, proportional to MrP1 expression. In conclusion, this study demonstrates that increased cellular folate concentrations induce MrP1/aBCC1-related drug efflux and drug resistance. these results have important implications in the understanding of the role of MrP1 and its homologs in clinical drug resistance.
Introduction
Folates are vitamins that are daily required for many biosynthetic processes. as one-carbon donors and cofactors, they play a role in the synthesis of amino acids (methionine, serine), de novo purine synthesis, and synthesis of thymidylate for Dna synthesis [1] . In addition, folates influence gene expression via Dna methylation, as a result of methionine production from homocysteine and methyltetrahydrofolate.
Folate supplementation to the diet was earlier reported to protect against cancer and other diseases [2] [3] [4] . later, warnings were given that an abundant intake of folate might promote tumorigenesis of existing neoplasia [5, 6] . recently, however, meta-analyses indicated that folic acid supplementation does not affect incidence of site-specific cancer during the first years of folate treatment [7, 8] .
Abstract Cellular folate concentration was earlier reported to be a critical factor in the activity and expression of the multidrug resistance protein MrP1 (aBCC1). Since MrP1 mediates resistance to a variety of therapeutic drugs, we investigated whether the cellular folate concentration influences the MrP1-mediated cellular resistance against drugs. as a model system, we used the human ovarian carcinoma cell line 2008wt, and its stably MrP1/aBCC1-transfected subline 2008/MrP1. these cell types have a moderate and high expression of MrP1, respectively. In folate-deprived 2008/MrP1 cells, the MrP1-mediated efflux of its model substrate calcein decreased to ~55 % of the initial efflux rate under folaterich conditions. In 2008wt cells, only a small decrease in efflux was observed. Folate depletion for 5-10 days markedly increased (~500 %) cellular steady-state accumulation Folate supplementation has become an essential part of certain cancer chemotherapeutic regimens, since it reduces toxicity of antifolate-based treatments [9] . For instance, the folate leucovorin is commonly used to reduce antifolate toxicity in leukemias and several solid tumors [9, 10] . also, combination of the antifolate alimta (pemetrexed) with cisplatin was less toxic after folic acid supplementation [11] , and folic acid not only increased the efficacy of this combination, but also that of cisplatin as a single drug.
nowadays, there is growing evidence that dietary supplements such as folic acid can mimic, intensify, or attenuate the effects of chemotherapeutic agents [12] .
One mechanism by which folates might influence chemotherapy is via their interaction with transporter proteins that cause multiple drug resistance (MDr). We earlier demonstrated, for instance, that folates enhance the cellular efflux of the anticancer agent daunorubicin (Dnr)-mediated by the multidrug resistance protein 1 (MrP1/aBCC1) [13] . MrP1 is the founding member of the C-subclass of atP-binding cassette (aBC) transporters. Most of the nine MrP/aBCC members are lipophilic anion pumps that transport a range of structurally unrelated therapeutic drugs and other xenobiotics, as well as several physiologically important organic anions such as leukotriene C(4) and prostaglandin e2 out of the cell [14] [15] [16] [17] [18] [19] [20] [21] [22] . like other aBC transporters, such as P-glycoprotein (P-gp/aBCB1) and the breast cancer resistance protein (BCrP/aBCg2), expression of MrPs in cancer cells can confer resistance to a broad variety of anticancer agents. For detailed information on MrP1 and its homologs, we refer to recent reviews [21, 22] .
We and others reported that antifolates, including methotrexate (MtX), are good substrates of most MrPs [20] [21] [22] [23] [24] [25] [26] . these agents are structural analogs of natural reduced folates and act as antagonists of cellular folate metabolism. MtX is used in the treatment of several types of cancer and inflammatory diseases [1, 27] . Second generation antifolates such as raltitrexed (ZD1694) and alimta are registered for clinical use [28, 29] .
In addition to MtX, also natural folates, such as folic acid and leucovorin, were identified as substrates of MrPs [24] [25] [26] 30] . accordingly, many MrPs play a role in antifolate resistance and in controlling cellular homeostasis of natural folates [30] .
the above-mentioned observation that folates enhance the MrP1-mediated efflux of Dnr was ascribed to an induction of MrP1 transport activity, rather than to an increase in expression level of MrP1 [13] . this raised the question whether folate supplementation not only enhances MrP1 transport activity, but also induces MrP1-mediated cellular drug resistance to Dnr and other anticancer agents.
In this study, we investigated whether folates provoke drug resistance to Dnr and structurally unrelated MrP1 substrates. In addition, since Dnr is a positively charged agent, we now also studied whether folates induce cellular efflux of negatively charged compounds.
Materials and methods

reagents and cell lines
Folic acid, l-leucovorin (lV), verapamil (Vp), and digitonin were obtained from Sigma Chemical Co. (St. louis, MO). Protease inhibitor cocktail was purchased from Boehringer, nl. normal rPMI-1640 medium (which contains 2.3 μM folic acid), folate-free rPMI-1640 medium, normal fetal calf serum, and dialyzed fetal calf serum were obtained from gIBCO (grand Isl., nY). Daunorubicin HCl (Dnr) was from Specia (Paris, France). Doxorubicin HCl (DOX) was obtained from Montedison nederland (rotterdam, the netherlands). MtX was a gift from Pharmachemie (Haarlem, the netherlands). Calcein-aM and the Dna probe Syto 13 were from Molecular Probes (eugene, Or). the MrP1 inhibitor MK571 (l-660,711) was obtained from Dr. robert Zamboni (Merck-Frost, Pointe-Claire, Quebec, Canada).
the human ovarian carcinoma cell line 2008wt, which expresses a basic level of MrP1, and its stable MrP1 transfectant 2008/MrP1 were kindly provided by Prof. Dr. P. Borst (the netherlands Cancer Institute, amsterdam). these cell lines were cultured in rPMI 1640 medium, supplemented with 10 % FCS, 2 mM glutamine, and 100 μg/ml penicillin/streptomycin. this culture medium is factory-supplied with 2.3 μM folic acid. For folate deprivation, cells were cultured for 2 days in special folic acid-free rPMI 1640 medium supplemented with 10 % dialyzed FCS, 2 mM glutamine, and 100 μg/ml penicillin/ streptomycin. growth inhibition Cells (1 × 10 4 -1.75 × 10 4 /well) were seeded in 1 ml of culture medium in 24-well plates and cultured at 37 °C. Cells were allowed to attach for 24 h. Cells were then exposed to various concentrations of the drugs covering a three-log range for either 4 h (MtX) or 72 h (other drugs). Following the 4-h exposure to MtX, the medium was aspirated, and the cells were washed thrice with 2.5 ml drug-free medium at 37 °C. thereafter, the cells were cultured for an additional 68 h at 37 °C. after 72 h, cells were detached by trypsinization, and the cells were counted using a microcell counter. Finally, drug concentrations inhibiting 50 % growth inhibition (IC50) were determined.
Cellular calcein accumulation
Steady-state cellular accumulation of calcein was measured using a method described by Feller et al. [31] with several modifications. Cells were plated in a 96-wells plate at a density of 2000 cells/well, 1 day prior to the measurement. Cells were either cultured in folate-free or folate-rich medium (2.3 μM folic acid). the next day, all cells were exposed to 10 μM calcein-aM for 30 min. thereafter, fluorescence of the formed calcein was measured in a fluorescence meter, type SpectraFluor (tecan austria gmbh, groedig, austria). the maximal level of calcein accumulation was determined in control cells by adding 100 μM of the MrP1 inhibitor MK-571 [32] 10 min prior to the calcein-aM exposure.
Cellular drug efflux efflux of fluorescent calcein was measured using an online computerized method described by Wielinga et al. [33] . In brief, cells were cultured on glass coverslips that fitted to the wall of a cuvette of 1 × 1 × 4 cm (width, depth, and height). to load the cells with substrate, the coverslips were placed in a petri dish containing culture medium (37 °C), 1 μM calcein-aM, and 150 μM Verapamil (to block MrP1-mediated efflux during the loading period) until steady state was reached (≥2 h). after loading, the cells were put on ice until further use.
For an efflux experiment, a coverslip was washed twice with ice-cold medium a (rPMI medium without phenol red). the coverslip was placed in the cuvette that contained 3-ml warm (37 °C) medium a. the fluorescence of the effluxed substrate appearing in the medium was monitored with a spectrafluorometer (FluoroMax, SPeX Industries, edison, nJ). Fluorescence of calcein was measured every second at excitations and emission wavelengths of 492 and 530 nm, respectively. at the end of the experiment, 25 μM digitonin was added to permeabilize the cells and to determine the total amount of intracellular Dnr. next, the cell number was determined by adding 400 nM of the Dna probe Syto 13. the Dnr signals were normalized for the Syto 13 signals. the fluorescence of Syto 13 was determined at excitation wavelength of 485 nm and emission wavelength of 520 nm. nucleotide levels extraction of nucleotides from cells was performed as described previously [34] . Subsequently, separation and quantification of the nucleotide pools were done using a gradient HPlC system consisting of two gyncotek pumps (model 300, Separation analytical Instruments BV, Hendrik Ido ambacht, the netherlands), as described earlier [34] . the HPlC system was connected to a photo-diode array detector (Separations, model 1000S), regularly set at 254 and 280 nm. Chromatography peaks were quantitated using the data acquisition program Chromeleon 3.02. (Fig. 1) . after folate depletion for 48 h, the calcein efflux rate was about twofold decreased in the MrP1-transfected cells compared with folate-rich conditions. also in the wild type cells, a significant reduction in calcein efflux (albeit smaller) could be observed.
Results
Folate
We also examined the influence of cellular folate concentration on the steady-state accumulation of calcein in (Fig. 2) . exposure to the MrP1 inhibitor MK571 completely equalized calcein accumulation between these two cell lines. When cultured in folate-free medium for up to 10 days, the accumulation of calcein in 2008/MrP1 cells gradually increased fivefold (Fig. 3a) . although less, even in 2008wt cells, a significant increase in calcein accumulation could be observed after folate depletion (Fig. 3b) .
In Fig. 4 , the effect on cellular calcein accumulation of a 24-h exposure to l-leucovorin after a folate-free period is shown. In the MrP1-overexpressing cells, this short-term l-leucovorin supplementation resulted in a restored calcein level that was comparable to levels found in continuous folate-rich conditions (Fig. 4) .
Cellular nucleotide levels
Because the MrP1-mediated efflux of its substrates is energy-dependent, we verified whether cellular atP levels remained sufficient during folate-free culture conditions. During the first 7 days of folate depletion, no significant decrease in atP or other nucleotides was observed. Over a 10 days culture period in folate-free medium, atP levels gradually decreased to about half of those in both 2008wt and 2008/MrP1 cells (data not shown).
Increased folate concentration enhances MrP1-mediated drug resistance as shown above, the cellular folate concentration is a determining factor in the transport activity of MrP1. It might therefore impact MrP1-mediated MDr. In order to study this, we performed growth inhibition experiments under different cellular folate conditions using the anthracyclines Dnr, and DOX, as well as MtX, vincristine and etoposide. all these agents are established MrP1 substrates. the IC50 values for these drugs were determined in 2008wt and 2008/MrP1 cells that were cultured in either folic acidfree medium or in folate-rich medium for 3 days. to prevent polyglutamylation of MtX, which promotes cellular retention, exposure time for this drug was 4 h, followed by 3-day drug-free culture.
Under folate-rich conditions, the 2008/MrP1 cells were highly resistant against all drugs compared with the 2008wt cells (Fig. 5) . resistance factors were 5.8-fold (DOX), 3.8-fold (Dnr), and 21.0-fold (MtX). When cultured in folate-free medium, however, the IC50 values for DOX and MtX were markedly lower in the MrP1-overexpressing cells (fivefold, and 83-fold, respectively). For Dnr, a smaller but significant decrease was observed. For vincristine and etoposide, however, toxicity was hardly affected by folate condition in 2008wt and 2008/MrP1 cells (data not shown).
Discussion
Folate supplementation is part of in several routine chemotherapy protocols to reduce drug toxicity [9, 10] . It also was reported as a strategy to increase antitumor activity [11, 12] .
In recent years, it became clear that folates also interact with aBC transporter proteins that play a role in MDr. Folic acid and leucovorin are, for instance, substrates of MrP1 and its homologs [24] [25] [26] 30] . However, the fact that many MDr pumps harbor the capacity to transport folates does not automatically imply that folates act as competitive inhibitors in MDr. We demonstrated in an earlier study that high cellular folate concentrations induce MrP1-mediated cellular efflux of the positively charged drug Dnr [13] . notably, two-day culture in folate-free medium decreased the total cellular Dnr efflux to 43 % in 2008/MrP1 cells and to 84 % in 2008wt cells. repletion of folate by a 2-24-h exposure completely restored of Dnr efflux in these cells. Based on these observations, we then postulated that folates apparently interact with MrP1 in a similar way as gluthathione (gSH) [35] .
gSH is crucial for MrP1-mediated transport of positively charged compounds like Dnr and DOX. Several studies debated on the exact role of gSH in MrP1 activity [36, 37] . gSH was described as a co-substrate in transport of positively charged drugs [36] and/or to form a conjugate with positively charged drugs [37] . Similarly, gSH and its non-reducing alkyl derivative S-methyl gSH were shown to stimulate MrP1 transport activity of endogenous compounds, rather than act as co-substrates or conjugates [38] . as proposed by Borst et al. [39] , the glutamate residue of gSH could be important in the binding to a reactive site in the MrP1 protein. like gSH, also folates contain a glutamate residue that might play a key role in its interaction with MrPs. In this present study, we showed that basal efflux of the negatively charged compound calcein by MrP1 is enhanced by folates. Calcein is not dependent on gSH for its transport by MrP1 [31] . although this contradicts an exact identical role for folates and gSH in MrP1 activity, it does support the postulation that MrP1 activity is subject to various modes of modulation.
Other mechanisms through which folates might influence MrP1 transport activity are open for consideration. a decrease in cellular atP levels as a result of altered cellular folate status was excluded in our study as a possible cause of decreased MrP1 activity. Increments of cellular homocysteine levels as a result of lowered folate status were reported [35] , but whether these influence MrP1 function is not clear. Finally, the cellular folate status can influence indirectly the regulation of gene expression through methylation of Cpg islands in the promoter region of a variety of genes [40, 41] . However, as we reported earlier, short folate depletion periods (<10 days) did not impact the expression level of MrP1 protein [13] . reports of loss of MrP1 expression upon prolonged (>3 months) folate deprivation [42] were probably due to a selection process, in which a decreased MrP1 expression is physiologically beneficial to withhold intracellular folates under folate-restricted conditions. an important issue is whether our "proof-of-principle" experiments in this study can be translated to MDr phenomena in patients. First, folate levels in human plasma, in normal human tissues, and in solid tumors normally vary between 5 and 20 nM 5-methyltetrahydrofolate [12, 43, 44] . these are approximately mimicked in the folatedeprived cells in vitro. In contrast, the "folate-rich" concentrations used in our study were supraphysiological and would only represent cases of extreme folate oversupplementation. Secondly, in the present study, we focused primarily on MrP1. Conceivably, however, in MDr, a much broader range of MrP1 homologs as well as other aBC transporter proteins may contribute, including BCrP and Pgp. the dynamic interplay between all of these transporters in a diversity of tissues and cell types has to be taken into account to fully understand the complete role of folates in MDr. expanding this study to other aBC transporters and clinically relevant physiological folate supplementation levels would merit further exploration.
In conclusion, folate supplementation during chemotherapy may have several impacts: reduction in toxicity, increase in antitumor activity, but also induction of MrP1 transport activity and cellular drug resistance. these latter effects of folate intake and folate levels during chemotherapy deserve ongoing considerations.
